This Week in Evolution is a podcast on the biology of what makes us tick. Hosts Nels Elde and Vincent Racaniello take you through the new evolution that has been revolutionized by the field of genomics and molecular biology.
…
continue reading
Player FM - Internet Radio Done Right
Checked 12h ago
जोड़े गए one साल पहले
David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist, David Brühlmann - CMC Development Leader, Biotech C-level Advisor, and Business Strategist द्वारा प्रदान की गई सामग्री. एपिसोड, ग्राफिक्स और पॉडकास्ट विवरण सहित सभी पॉडकास्ट सामग्री David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist, David Brühlmann - CMC Development Leader, Biotech C-level Advisor, and Business Strategist या उनके पॉडकास्ट प्लेटफ़ॉर्म पार्टनर द्वारा सीधे अपलोड और प्रदान की जाती है। यदि आपको लगता है कि कोई आपकी अनुमति के बिना आपके कॉपीराइट किए गए कार्य का उपयोग कर रहा है, तो आप यहां बताई गई प्रक्रिया का पालन कर सकते हैं https://hi.player.fm/legal।
समान Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up, Cell Culture Innovation
A myriad of AI, science, and technology experts explore the real challenges and enormous opportunities facing entrepreneurs who are building the future of health. Raising Health, a podcast by a16z Bio + Health and hosted by Kris Tatiossian and Olivia Webb, dives deep into the heart of biotechnology and healthcare innovation. Join veteran company builders, operators, and investors Vijay Pande, Julie Yoo, Vineeta Agarwala, and Jorge Conde, along with distinguished guests like Mark Cuban, Greg ...
…
continue reading
Flash Forward is a show about possible (and not so possible) future scenarios. What would the warranty on a sex robot look like? How would diplomacy work if we couldn’t lie? Could there ever be a fecal transplant black market? (Complicated, it wouldn’t, and yes, respectively, in case you’re curious.) Hosted and produced by award winning science journalist Rose Eveleth, each episode combines audio drama and journalism to go deep on potential tomorrows, and uncovers what those futures might re ...
…
continue reading
Going Wild with Dr. Rae Wynn Grant is a different kind of nature show about the human drama of saving animals. From a paleoanthropologist who hunts fossils in conflict zones to someone who helped save an endangered species while in prison, in season four we will hear from real-life heroes and nature advocates with widely different expertise and life experiences that led them to be champions for the natural world. Wildlife biologist and host Dr. Rae Wynn-Grant has been studying wild animals i ...
…
continue reading
Come dive into one of the curiously delightful conversations overheard at National Geographic’s headquarters, as we follow explorers, photographers, and scientists to the edges of our big, weird, beautiful world. Hosted by Peter Gwin and Amy Briggs.
…
continue reading
This Week in Microbiology is a podcast about unseen life on Earth hosted by Vincent Racaniello and friends. Following in the path of his successful shows 'This Week in Virology' (TWiV) and 'This Week in Parasitism' (TWiP), Racaniello and guests produce an informal yet informative conversation about microbes which is accessible to everyone, no matter what their science background.
…
continue reading
Best Business Podcast (Gold), British Podcast Awards 2023 How do you build a fully electric motorcycle with no compromises on performance? How can we truly experience what the virtual world feels like? What does it take to design the first commercially available flying car? And how do you build a lightsaber? These are some of the questions this podcast answers as we share the moments where digital transforms physical, and meet the brilliant minds behind some of the most innovative products a ...
…
continue reading
Unexplainable takes listeners right up to the edge of what we know…and then keeps on going. The Unexplainable team — Noam Hassenfeld, Julia Longoria, Byrd Pinkerton, and Meradith Hoddinott — tackles scientific mysteries, unanswered questions, and everything we learn diving into the unknown. New episodes every Wednesday.
…
continue reading
The surprising connections in science and technology that give you the Big Picture. Astronomer Seth Shostak and science journalist Molly Bentley are joined each week by leading researchers, techies, and journalists to provide a smart and humorous take on science. Our regular "Skeptic Check" episodes cast a critical eye on pseudoscience.
…
continue reading
The Naked Scientists flagship science show brings you a lighthearted look at the latest scientific breakthroughs, interviews with the world's top scientists, answers to your science questions and science experiments to try at home.
…
continue reading
Player FM - पॉडकास्ट ऐप
Player FM ऐप के साथ ऑफ़लाइन जाएं!
Player FM ऐप के साथ ऑफ़लाइन जाएं!
))
Daily Deals
Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up, Cell Culture Innovation
«
»
73: Bead-Based Assays: The Power of High-Throughput Screening w/ Sebastian Giehring - Part 1
Manage episode 430310787 series 3525243
David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist, David Brühlmann - CMC Development Leader, Biotech C-level Advisor, and Business Strategist द्वारा प्रदान की गई सामग्री. एपिसोड, ग्राफिक्स और पॉडकास्ट विवरण सहित सभी पॉडकास्ट सामग्री David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist, David Brühlmann - CMC Development Leader, Biotech C-level Advisor, and Business Strategist या उनके पॉडकास्ट प्लेटफ़ॉर्म पार्टनर द्वारा सीधे अपलोड और प्रदान की जाती है। यदि आपको लगता है कि कोई आपकी अनुमति के बिना आपके कॉपीराइट किए गए कार्य का उपयोग कर रहा है, तो आप यहां बताई गई प्रक्रिया का पालन कर सकते हैं https://hi.player.fm/legal।
Ready to revolutionize your lab work? Join us as we dive deep into bead-based assays with Sebastian Giehring, CEO and founder of PAIA Biotech.
Discover how these tiny beads are making a massive impact on biotech research and development — for titer, glycan, and aggreation screening — and how this developability screening platform can enhance your antibody discovery, antibody engineering and lead optimization.
In this episode, you’ll learn:
- Speed and Simplicity: How bead-based assays offer unmatched throughput and ease of use, allowing you to analyze hundreds of samples in just a few steps.
- Versatile Applications: The diverse applications of bead-based assays in cell development, bioprocessing, and antibody discovery, helping streamline workflows and enhance innovation.
- Early Screening Advantages: The benefits of bead-based assays in early-stage process development, enabling quick decision-making with less detailed but rapid results.
Tune in to uncover how these assays can transform your biotech research and push the boundaries of what's possible!
Connect with Sebastian Giehring:
LinkedIn: https://www.linkedin.com/in/sebastian-giehring-6ba1992
PAIA Biotech: https://www.paiabio.com
Next Steps:
Book a free assessment to help you get started with the design of your next experiment at https://bruehlmann-consulting.com
Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com
148 एपिसोडस
साझा करेंManage episode 430310787 series 3525243
David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist, David Brühlmann - CMC Development Leader, Biotech C-level Advisor, and Business Strategist द्वारा प्रदान की गई सामग्री. एपिसोड, ग्राफिक्स और पॉडकास्ट विवरण सहित सभी पॉडकास्ट सामग्री David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist, David Brühlmann - CMC Development Leader, Biotech C-level Advisor, and Business Strategist या उनके पॉडकास्ट प्लेटफ़ॉर्म पार्टनर द्वारा सीधे अपलोड और प्रदान की जाती है। यदि आपको लगता है कि कोई आपकी अनुमति के बिना आपके कॉपीराइट किए गए कार्य का उपयोग कर रहा है, तो आप यहां बताई गई प्रक्रिया का पालन कर सकते हैं https://hi.player.fm/legal।
Ready to revolutionize your lab work? Join us as we dive deep into bead-based assays with Sebastian Giehring, CEO and founder of PAIA Biotech.
Discover how these tiny beads are making a massive impact on biotech research and development — for titer, glycan, and aggreation screening — and how this developability screening platform can enhance your antibody discovery, antibody engineering and lead optimization.
In this episode, you’ll learn:
- Speed and Simplicity: How bead-based assays offer unmatched throughput and ease of use, allowing you to analyze hundreds of samples in just a few steps.
- Versatile Applications: The diverse applications of bead-based assays in cell development, bioprocessing, and antibody discovery, helping streamline workflows and enhance innovation.
- Early Screening Advantages: The benefits of bead-based assays in early-stage process development, enabling quick decision-making with less detailed but rapid results.
Tune in to uncover how these assays can transform your biotech research and push the boundaries of what's possible!
Connect with Sebastian Giehring:
LinkedIn: https://www.linkedin.com/in/sebastian-giehring-6ba1992
PAIA Biotech: https://www.paiabio.com
Next Steps:
Book a free assessment to help you get started with the design of your next experiment at https://bruehlmann-consulting.com
Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com
148 एपिसोडस
All episodes
×
S
Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up, Cell Culture Innovation
1 147: Lab-Grown Blood: How Stem Cells Transform Transfusions with Ari Gargir - Part 1 22:01
22:01 
बाद में चलाएं 
बाद में चलाएं 
सूचियाँ 
पसंद 
पसंद22:01
बाद में चलाएं बाद में चलाएं सूचियाँ पसंद पसंदSend us a text Blood is critical to global healthcare - vital for surgeries, trauma care, cancer treatment, and maternal health. Yet despite 120 million donations each year, a 100 million unit shortfall means nearly half the world’s needs go unmet. One person who understands this crisis firsthand is Ari Gargir, CEO & Founder of RedC Biotech. After surviving a paragliding accident thanks to a life-saving transfusion, he set out to tackle the global blood shortage. His team is now developing universal, lab-grown red blood cells, eliminating the need for donors. The added transitional phrase creates a smoother flow between the global problem and the personal story that follows. Don’t miss these key insights from the full conversation: The Global Crisis: Ari painted a vivid picture of the current state of blood supply. The problem is multifaceted - logistical issues, biological challenges, and socio-economic disparities in blood distribution exacerbate this shortage. Developed nations possess more blood resources, but low-income countries, where donation rates are staggeringly low, continually grapple with severe shortages. Innovative Solutions: We learned about the groundbreaking technology Ari is developing at RedC Biotech. Using stem cells, they aim to create unlimited, universal, and donor-free red blood cells. This could be a game-changer, not only for transfusions but also for advanced therapeutic uses. Impact on Healthcare : Ari is a strong advocate for O-negative blood, which can be used for up to 98% of people. But he’s especially focused on vulnerable patients - those with sickle cell disease, thalassemia, and complex immune conditions - who may need frequent transfusions. Our conversation with Ari underscores the importance of innovation in biotechnology to address critical global healthcare issues. By creating a reliable, scalable supply of red blood cells, RedC Biotech holds the promise of saving countless lives and improving the quality of life for those dependent on regular blood transfusions. Tune in to hear how Ari and RedC Biotech are shaping the future of transfusion medicine. Connect with Ari Gargir: LinkedIn: www.linkedin.com/in/ari-gargir-7107035 RedC Biotech: www.redcbiotech.com Next step: Transform your bioprocess development strategy with a complimentary consultation. Schedule your expert session: https://bruehlmann-consulting.com/call Ready to scale up? Join our exclusive 1:1 Strategy Call and learn proven methods to reduce development and manufacturing costs while maintaining product quality. Our bioprocess experts will help you navigate complex bioprocessing challenges and regulatory requirements. Limited spots available: https://stan.store/SmartBiotech…
S
Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up, Cell Culture Innovation
1 146: Beyond ELISA: The 10-Minute Immunoassay Enabling Real-Time Bioprocess Control with Bruno Oesch - Part 2 18:09
18:09 बाद में चलाएं बाद में चलाएं सूचियाँ पसंद पसंद18:09
बाद में चलाएं बाद में चलाएं सूचियाँ पसंद पसंदSend us a text Stuck with outdated analytics while trying to develop cutting-edge therapies? Part 2 of our conversation with Bruno Oesch, CEO and founder of Elionova, reveals how biotech scientists can finally break free from incremental improvements and embrace the revolutionary immunoassay technology that's transforming bioprocessing workflows worldwide. For years, ELISA (Enzyme-Linked Immunosorbent Assay) has been vital in biotechnology, but its time-consuming protocols and complex washing steps slow bioprocess development, creating bottlenecks in advancing therapies. Bruno's team is transforming the field of immunoassays with an innovative technology that delivers quantitative results in just 10 minutes—without the need for washing steps. Here are three key takeaways from the conversation: Market Introduction Strategy : Bruno emphasizes the importance of placing the product directly in the hands of potential customers. By offering free trials, users can experience its value firsthand, creating a strong incentive for continued use. Building an Open Community : Elionova fosters a collaborative environment where users can develop and share assays. Their vision follows an app store model, encouraging innovation and knowledge exchange within the biotech space. Vision for the Future : Beginning with research labs, Elionova aims to expand into diagnostics, particularly in veterinary medicine, due to lower regulatory hurdles. Their long-term goal is to make a significant impact in point-of-care diagnostics, offering rapid results crucial for emergency medical scenarios. If you're a biotech professional looking to streamline bioprocess workflows and drive innovation, Bruno Oesch’s transformative approach may provide the inspiration you need. Stay ahead of industry advancements by tuning into this episode to learn more about connecting with Oesch and exploring Elionova’s novel technology. Connect with Bruno Oesch: LinkedIn: www.linkedin.com/in/bruno-oesch Elionova: www.elionova.com Next step: Ready to revolutionize your bioprocess workflows? Book a free consultation at https://bruehlmann-consulting.com/call to discover how real-time analytics can transform your development timeline.…
S
Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up, Cell Culture Innovation
1 145: Beyond ELISA: The 10-Minute Immunoassay Enabling Real-Time Bioprocess Control with Bruno Oesch - Part 1 27:19
27:19 बाद में चलाएं बाद में चलाएं सूचियाँ पसंद पसंद27:19
बाद में चलाएं बाद में चलाएं सूचियाँ पसंद पसंदSend us a text Tired of waiting overnight for ELISA results? Serial entrepreneur Bruno Oesch reveals how his groundbreaking 10-minute immunoassay technology is eliminating the biggest bottleneck in bioprocessing workflows. From contributing to Nobel Prize-winning prion research to founding Prionics (the first commercial BSE test) and now revolutionizing immunoassays with Elionova, Bruno transforms high-end science into practical solutions that work for everyday labs. Here are three takeaways from this podcast episode: ELISA - The Lab Workhorse That Still Matters : Since the 1970s, ELISA assays have been a cornerstone of bioprocessing and diagnostics. As Bruno Oesch puts it, they remain the "workhorses of biochemical labs." Despite requiring over four hours of binding and washing steps, ELISA remains widely used for its affordability and reliability. However, its slow, linear workflow calls for innovation. ElioDX - The Next-Gen Immunoassay : While Elionova didn’t invent evanescence, they’ve made it accessible and practical. Instead of lengthy washes, a laser-generated evanescent field enables real-time detection, delivering results in just 10 minutes by measuring signal changes dynamically. The Future of Real-Time Bioprocessing: This breakthrough eliminates bottlenecks in biotech workflows. By integrating real-time analysis, ElioDX enhances efficiency, decision-making, and continuous bioprocessing, ensuring precise insights exactly when they’re needed. As David and Bruno highlight, the future of immunoassays isn’t just about innovation - it’s about making these advancements practical and transformative across the industry. By bridging science and accessibility, leaders like Bruno Oesch play a crucial role in demystifying bioprocessing, sparking impactful discussions, and driving real change in the scientific community. Listen to the full discussion to explore how this real-time approach can streamline bioprocessing and transform your workflows. Connect with Bruno Oesch: LinkedIn: www.linkedin.com/in/bruno-oesch Elionova: www.elionova.com Next step: Book a free consultation to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at https://stan.store/SmartBiotech…
S
Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up, Cell Culture Innovation
1 144: The Future of Biotech: Making Biotherapeutics More Accessible Faster 12:55
12:55 बाद में चलाएं बाद में चलाएं सूचियाँ पसंद पसंद12:55
बाद में चलाएं बाद में चलाएं सूचियाँ पसंद पसंदSend us a text Imagine a future where every patient can access life-saving therapies and sustainable, high-quality food is within everyone’s reach. In this episode of the Smart Biotech Scientist , David Brühlmann explores how innovative biotech developments are making this vision a reality. Here’s a sneak peek of the breakthroughs covered: AI-Powered Picoliter Scale Testing : Discover how companies like Triple Bar Bio are pushing the boundaries of what's possible with their innovative microfluidic technology that screens individual cells. Their approach enables rapid identification the best cell producers, paving the way for more efficient and precise bio-manufacturing. Hybrid Models for Process Prediction : Learn about DataHow's cutting-edge hybrid models that predicts process outcomes and improves product quality. Their models have demonstrated the potential to reduce the number of experiments by up to 80%. Unconventional Bioreactor Approaches : Explore an intriguing proposition – could tomorrow's bioreactors be living organisms like goats? BioSourcing is exploring the potential of transgenic goats to produce biopharmaceuticals more affordably, a concept that could dramatically lower production costs and enhance accessibility. The future of biotech is not just about technological advancement; it’s about embracing the impact these innovations can have globally. As David urges, the challenge is no longer about if these changes will happen, but how quickly we can achieve them. Stay curious, keep innovating, and be part of this exciting transformation in biotech. Your contributions and feedback could shape the next generation of breakthroughs. Listen, learn, and let us know what you think about these advancements. We can’t wait to hear from you! If you enjoyed this, here are some episodes worth listening: Episode 135: Beyond Breakthroughs: Making Biotherapeutics Affordable for All Episode 136: 5 Roadblocks to Affordable Biologics (And How to Overcome Them) Episodes 127-128: The 7 Hidden Innovation Habits That Top Biotech Scientists Use Daily Episode 87: The Hidden Pitfalls of Bioprocess Development: Lessons from the Trenches Episodes 41-42: Revealing the Disciplined Pursuit of Less in Bioprocessing Next step: Wondering how to develop biomanufacturing processes with peace of mind? Schedule your free consultation to propel your success: https://bruehlmann-consulting.com/call Develop biotherapeutics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech…
S
Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up, Cell Culture Innovation
1 143: Bioprocess Breakthroughs: How Smart Bioprocessing Is Democratizing Life-Saving Treatments 15:32
15:32 बाद में चलाएं बाद में चलाएं सूचियाँ पसंद पसंद15:32
बाद में चलाएं बाद में चलाएं सूचियाँ पसंद पसंदSend us a text In the rapidly evolving world of biotechnology, innovation is not just happening at the molecular level. Industry leaders are making groundbreaking advancements in bioprocessing - a crucial component in making life-saving therapies more accessible and affordable. The journey to affordable therapies starts with the production process itself. In this podcast episode, David Brühlmann sheds light on innovations in bioprocess design that are setting new standards in efficiency and efficacy. At the heart of this transformation is the shift from traditional process formats like fed-batch to continuous process formats, quality by design approaches, and the implementation of breakthrough technologies. Here's a quick rundown of the key takeaways: Revolutionary Process Designs : Industry leaders are enhancing bioprocess designs—from antibody production enhancements to integrating perfusion mode. One case study highlighted a dramatic increase in viable cell density and protein titers through intensified processes. Quality Control Innovations : Companies like Cyto-Facto are pioneering quality by design in the challenging cell and gene therapy space. By leveraging sophisticated PAT systems, they can monitor critical process parameters in real-time, ensuring consistent quality even in complex bioprocesses. Metabolite Shifts and Efficacy : A surprising discovery revealed the power of metabolite shifts induced by cell culture media design, inspired by an intriguing study on cyclists, to enhance antibody efficacy and stability. This opens new possibilities for engineering the quality of biopharmaceuticals through simple modifications in the culturing process. The innovations discussed in the Smart Biotech Scientist illustrate a pivotal transformation in bioprocessing. By rethinking process designs and committing to quality control, the biotech industry is paving the way for groundbreaking therapies that are not just dreams but realities - realities that are tangibly more accessible to patients worldwide. As we anticipate more developments in this field, the promise of biotech becomes increasingly certain: a future where life-saving treatments are affordable and available to all who need them. Catch the full episode to explore how these innovations are not just improving efficiency but making life-saving therapies more accessible globally. If you enjoyed this, here are some episodes worth listening: Episode 135: Beyond Breakthroughs: Making Biotherapeutics Affordable for All Episode 136: 5 Roadblocks to Affordable Biologics (And How to Overcome Them) Episodes 127-128: The 7 Hidden Innovation Habits That Top Biotech Scientists Use Daily Episode 87: The Hidden Pitfalls of Bioprocess Development: Lessons from the Trenches Episodes 41-42: Revealing the Disciplined Pursuit of Less in Bioprocessing Next step: Wondering how to develop biomanufacturing processes with peace of mind? Schedule your free consultation to propel your success: https://bruehlmann-consulting.com/call Develop biotherapeutics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech…
S
Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up, Cell Culture Innovation
1 142: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel Bardor - Part 2 17:06
17:06 बाद में चलाएं बाद में चलाएं सूचियाँ पसंद पसंद17:06
बाद में चलाएं बाद में चलाएं सूचियाँ पसंद पसंदSend us a text What if we could revolutionize biotechnology by slashing antibody production costs by 70%? In a world where traditional mammalian cell cultures struggle with scalability and cost-effectiveness, an unexpected hero emerges from the depths of our oceans - microalgae. The use of microalgae in biotechnology is not just a novelty but a necessity, given the current demands for more efficient and cost-effective production methods. Muriel Bardor, co-founder, CEO and CSO of Alga Biologics, highlights a particularly startling statistic: microalgae can reduce the cost of antibody production by an impressive 70%. This innovation could revolutionize the biotechnology industry by making life-saving therapies more accessible. Here are 3 key takeaways from this podcast episode: Quality and Safety Assurance : By collaborating with virology experts and using advanced techniques like mass spectrometry, they ensure that their processes are virus-free and free from host-cell protein contamination. The company is paving the way for future developments despite the challenges of not having standard ELISA kits commercially available. Regulation and Industry Perception: Launching such transformative technology inevitably entwines with regulatory landscapes. Muriel and her company have begun discussions with the French regulatory agency, drawing optimism from the fact that similar plant-based products, such as glucocerebrosidase, have already paved the way in the market. This indicates a growing acceptance within regulatory bodies of alternative bioprocessing platforms, inspiring hope for microalgae's future in antibody production. Future Vision : Muriel hopes to break conservative barriers within pharmaceutical companies and promote the adoption of microalgae production. This offers not only cost-effective solutions but also holds potential for new treatment options, like for neuroblastoma. Check out the episode to hear Muriel's advice for aspiring scientists and the general public alike regarding the future of research and the well-being of our planet. Connect with Muriel Bardor: LinkedIn: www.linkedin.com/in/muriel-bardor-47953024 Email: muriel.bardor@univ-rouen.fr Alga Biologics: www.algabiologics.com Next step: Book a free consultation to refine your CMC strategy to propel your success: https://bruehlmann-consulting.com/call Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at https://stan.store/SmartBiotech…
S
Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up, Cell Culture Innovation
1 141: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel Bardor - Part 1 25:15
25:15 बाद में चलाएं बाद में चलाएं सूचियाँ पसंद पसंद25:15
बाद में चलाएं बाद में चलाएं सूचियाँ पसंद पसंदSend us a text The world of biologics manufacturing is about to be transformed by a breakthrough that slashes antibody production costs by 70%. This revolutionary approach leverages the untapped potential of microalgae to deliver a sustainable, cost-effective solution that could make life-saving therapeutics more accessible than ever before. Enter microalgae, the star of this groundbreaking development. In this episode of the Smart Biotech Scientist, Muriel Bardor, the co-founder, CEO and CSO of Alga Biologics, shared insights into how her team's pioneering work with microalgae could redefine the landscape of immunotherapy. Here are some takeaways from her conversation with David Brühlmann: Green Revolution in Bioprocessing: Discover how microalgae can slash production costs by 70% and offer a sustainable alternative to traditional antibody manufacturing. Muriel explains how these photosynthetic organisms capture 7 tons of CO2 per kilogram of product - transforming antibody manufacturing both economically and environmentally. Rethinking Antibody Production: Learn why the conventional use of mammalian cells in antibody production is being challenged and how microalgae overcome the limitations of traditional methods, bringing life-saving drugs within reach for more people globally. Sustainable Impact: With a process that mirrors nature, Muriel’s approach sets a new standard for eco-friendly biotech production. Find out how microalgae are changing not just the industry, but our world. We invite you to listen to this insightful conversation and explore how you can apply these groundbreaking ideas to your own work. Has Muriel’s innovative approach inspired you? Share your thoughts or questions with us - we'd love to hear from you! If you are interested in antibody production, here is another episode worth listening: Episodes 47-48: Mastering Process Economics: Driving Down Costs in Antibody Production with Brian Kelley Connect with Muriel Bardor: LinkedIn: www.linkedin.com/in/muriel-bardor-47953024 Email: muriel.bardor@univ-rouen.fr Alga Biologics: www.algabiologics.com Next step: Book a free consultation to refine your CMC strategy to propel your success: https://bruehlmann-consulting.com/call Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at https://stan.store/SmartBiotech…
S
Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up, Cell Culture Innovation
1 140: Regulatory Secrets Revealed: Why Your CMC Strategy Could Make or Break Your Biotech Startup with Rivka Zaibel - Part 2 20:42
20:42 बाद में चलाएं बाद में चलाएं सूचियाँ पसंद पसंद20:42
बाद में चलाएं बाद में चलाएं सूचियाँ पसंद पसंदSend us a text In this episode, we explore the important steps in preparing for regulatory meetings, address the dangers of cross-contamination in biotechnology facilities, and debunk common misconceptions that could derail your CMC development strategy. As the founder and president of ADRES - Advanced Regulatory Services Ltd., Rivka Zaibel brings over 36 years of industry experience and practical strategies to help navigate the intricacies of CMC development and regulatory compliance. Here are three key takeaways: Risk Assessment is Paramount : Start risk assessments in parallel with facility design to prevent cross contamination. Remember, areas for both mammalian and microbial cells should be segregated to ensure safety. Early Engagement with Regulatory Agencies : Don’t wait until everything is finalized before consulting with regulatory bodies. Engaging them early can ensure your plans align with their requirements and might even spark valuable advice you hadn’t considered. Understand and Plan Your Product Journey : Have a clear vision of your final product from the start, and plan backwards. This approach ensures all supporting processes are adequately addressed, saving time and preventing costly mistakes down the line. Ultimately, successful biologics development hinges on thorough understanding and strategic planning. This includes comprehensive risk assessments, early regulatory engagement, and a commitment to continuous training and facility validation. Rivka's insights offer a roadmap for navigating this complex landscape, aiming to deliver groundbreaking therapies with precision and compliance. By following these expert strategies, biotech professionals can streamline their processes, avoid common pitfalls, and ensure the successful introduction of their products to the market. Connect with Rivka Zaibel: LinkedIn: www.linkedin.com/in/rivka-zaibel/ ADRES - Advanced Regulatory Services Ltd.: www.adres.bio Email: tanya@adres.bio Next step: Book a free consultation to refine your CMC strategy to propel your success: https://bruehlmann-consulting.com/call Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech…
S
Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up, Cell Culture Innovation
1 139: Regulatory Secrets Revealed: Why Your CMC Strategy Could Make or Break Your Biotech Startup with Rivka Zaibel - Part 1 25:21
25:21 बाद में चलाएं बाद में चलाएं सूचियाँ पसंद पसंद25:21
बाद में चलाएं बाद में चलाएं सूचियाँ पसंद पसंदSend us a text In biotherapeutic drug development, the journey from discovery to clinic involves navigating a labyrinth of regulatory requirements and strategic considerations, particularly in Chemistry, Manufacturing, and Control (CMC). In this episode of the Smart Biotech Scientist , host David Brühlmann engaged with Rivka Zaibel, President and Founder of ADRES - Advanced Regulatory Services Ltd. - to demystify the regulatory intricacies of biologics development and provide actionable insights for biotech leaders. With over three decades of experience in the biopharmaceutical industry, Rivka Zaibel highlights that understanding the regulatory landscape is crucial for the success of biologics development. Here are three key takeaways from this episode: Prioritize CMC Development Early : CMC (Chemistry, Manufacturing, and Controls) development is crucial in biologics. Rivka emphasizes starting early and engaging with regulatory agencies to avoid costly delays and streamline the bioprocessing journey. Understand Regulatory Differences : Different agencies (FDA vs. EMA) may have varied interpretations of guidelines. Familiarize yourself with ICH guidelines and the specific requirements of each agency to align your strategy effectively. Leverage Existing Resources : Before developing your own product pathway, explore existing European Public Assessment Reports (EPARs) and summary bases of approval for comparable products. This research can provide valuable insights into regulatory expectations and streamline your approach. For startups navigating the complexities of CMC development, Rivka highlights three critical quality and regulatory considerations essential for reaching Phase 1 trials. By embracing these key insights, biotech professionals can streamline the path to delivering innovative therapies to patients safely and efficiently. In conclusion, as you continue your journey within the biopharmaceutical industry, let the Smart Biotech Scientist serve as your guide, demystifying the complexities and empowering you with the tools needed to thrive. Stay informed, stay proactive! Connect with Rivka Zaibel: LinkedIn: www.linkedin.com/in/rivka-zaibel/ ADRES - Advanced Regulatory Services Ltd.: www.adres.bio Email: tanya@adres.bio Next step: Book a free consultation to refine your CMC strategy to propel your success: https://bruehlmann-consulting.com/call Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech…
S
Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up, Cell Culture Innovation
1 138: Skip 90% of Bioreactor Runs: The In Silico Revolution in Bioprocess Development with Yossi Quint - Part 2 20:16
20:16 बाद में चलाएं बाद में चलाएं सूचियाँ पसंद पसंद20:16
बाद में चलाएं बाद में चलाएं सूचियाँ पसंद पसंदSend us a text In the fast-evolving world of biotechnology, the pursuit of efficiency and faster development has never been more critical. The computational tools and models currently being integrated into bioprocessing present a groundbreaking approach that promises radical shifts in drug development timelines and capabilities. In the second part of our conversation, Yossi Quint, founder and CEO of Ark, shows us that the horizon of bioprocessing is lined with possibilities that could revolutionize biotherapeutics accessibility, cost, and speed in pharmaceutical innovations. Here are three key takeaways you don't want to miss: De-risking with Simulation : Yossi shared how simulation models can drastically reduce risks by running many scenarios before actual implementation. This approach optimizes processes, lowers costs, and speeds up the development cycle. Transfer Learning in Bioprocessing : Discover the potential of leveraging data across different types of molecules! Although challenging, the ultimate goal is to apply data learnings from one process to others, maximizing efficiency and success rates. Patient Impact & Cost Reduction : At the heart of these innovations is the goal of quicker, more affordable drug production. By slicing down on both time and costs, computational tools not only help drugs reach the market faster but also make them more accessible to patients globally. With innovation at its core, the modern trajectory of bioprocessing is not simply about reaching scientific milestones but about profoundly transforming patient care and accessibility. This synergistic blend of technology and purpose crafts a future in which the biotechnology sector not only grows but also enriches countless lives around the globe. If you are interested in this topic, here are a few standout conversations on AI’s impact on bioprocessing with some incredible experts: Episodes 131-132: Combining AI and Biomanufacturing for Sustainable, Cost-Effective Therapeutics with Reza Farahani Episodes 115-116: Revolutionizing Biologics Development with Hyper Throughput Screening and AI with Jeremy Agresti Episodes 111-112: AI Meets Biology: Why Domain Expertise Still Rules in the Age of Large Language Models with Lars Brandén Episodes 107-108: From 1 Billion to 100: How AI is Cracking the Enzyme Discovery Code with David Schönauer Episodes 95-96: AI in Bioprocess Development: The Game-Changer You Can't Ignore with Belma Alispahic Connect with Yossi Quint: LinkedIn: https://www.linkedin.com/in/yossi-quint Ark: https://www.ark-biotech.com Next step: Wondering how to develop biomanufacturing processes with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech…
S
Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up, Cell Culture Innovation
1 137: Skip 90% of Bioreactor Runs: The In Silico Revolution in Bioprocess Development with Yossi Quint - Part 1 21:55
21:55 बाद में चलाएं बाद में चलाएं सूचियाँ पसंद पसंद21:55
बाद में चलाएं बाद में चलाएं सूचियाँ पसंद पसंदSend us a text The integration of AI into drug discovery has already led to groundbreaking advancements, uncovering patterns in vast datasets that were previously invisible to human researchers. Now, AI is set to revolutionize bioprocessing as well. In this episode of the Smart Biotech Scientist Podcast , Yossi Quint, founder and CEO of Ark, and David Brühlmann explore how AI and computational tools are reshaping bioprocess development. Yossi envisions a future where 90% of bioreactor experiments could be replaced by in silico simulations , dramatically accelerating time to market and increasing throughput. Key takeaways from the conversation with Yossi Quint: AI’s Role in Drug Discovery & Bioprocessing: AI is already transforming drug discovery by identifying intricate patterns across millions of data points. Now, bioprocessing is undergoing a similar revolution, as computational tools simplify and streamline complex workflows. The Power of Hybrid Models: Yossi highlights the synergy between mechanistic models and AI-driven approaches , emphasizing how AI can fill gaps where traditional models struggle—especially in understanding complex cellular behaviors. Empowering Bioprocess Teams with AI: As AI accelerates drug discovery, bioprocessing must evolve to keep pace. Yossi discusses the importance of digital transformation in ensuring bioprocess teams can meet increasing demands and drive innovation forward. With AI-driven models, hybrid simulations, and increased digitization, the bioprocessing industry stands at the cusp of a new era. The convergence of data, science, and technology promises not only greater efficiency and accuracy but also a faster path to life-saving treatments for patients in need. If you want to learn more, here are a few standout conversations on AI’s impact on bioprocessing with some incredible experts: Episodes 131-132: Combining AI and Biomanufacturing for Sustainable, Cost-Effective Therapeutics with Reza Farahani Episodes 115-116: Revolutionizing Biologics Development with Hyper Throughput Screening and AI with Jeremy Agresti Episodes 111-112: AI Meets Biology: Why Domain Expertise Still Rules in the Age of Large Language Models with Lars Brandén Episodes 107-108: From 1 Billion to 100: How AI is Cracking the Enzyme Discovery Code with David Schönauer Episodes 95-96: AI in Bioprocess Development: The Game-Changer You Can't Ignore with Belma Alispahic Connect with Yossi Quint: LinkedIn: https://www.linkedin.com/in/yossi-quint Ark: https://www.ark-biotech.com Next step: Wondering how to develop biomanufacturing processes with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech…
S
Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up, Cell Culture Innovation
1 136: 5 Roadblocks to Affordable Biologics (And How to Overcome Them) 13:28
13:28 बाद में चलाएं बाद में चलाएं सूचियाँ पसंद पसंद13:28
बाद में चलाएं बाद में चलाएं सूचियाँ पसंद पसंदSend us a text Sickle cell disease affects thousands with severe daily pain. While FDA-approved gene therapies exist, their $2.2 million cost per treatment makes them largely inaccessible. In this episode of the Smart Biotech Scientist Podcast, David Brühlmann explores five key challenges facing the bioprocessing industry in making these therapies more accessible: Moving Away from Platform Technologies Traditional bioprocessing relies on platform technologies for antibody production. However, new therapies require more flexible, adaptable systems that can accommodate novel modalities. Increased Personalization and Smaller Batch Sizes Personalized medicine, especially autologous cell therapy, demands highly customized approaches. With batch sizes of one patient, traditional automation becomes challenging, requiring new methodologies. Cultivating Sensitive Cells Modern cell types need gentler handling than traditional CHO cells. Companies are developing innovative bioreactor technologies, from acoustic wave systems to stress-free cultivation methods. The Cell as the Product Cell-based products are billion times more complex than antibodies, requiring sophisticated production, monitoring, and quality control processes. Accessibility and Cost Challenges High treatment costs remain the biggest barrier. For example, only 21,000 of 900,000 eligible patients have received CAR T cell therapy due to financial constraints. Moving Forward Industry leaders across academia and pharma are collaborating to overcome these challenges through innovation and cost reduction. Every improvement brings us closer to making these treatments accessible to more patients. Join us on the Smart Biotech Scientist Podcast as we explore innovative solutions to these challenges. Next step: Wondering how to develop biomanufacturing processes with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech…
S
Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up, Cell Culture Innovation
1 135: Beyond Breakthroughs: Making Biotherapeutics Affordable for All 12:46
12:46 बाद में चलाएं बाद में चलाएं सूचियाँ पसंद पसंद12:46
बाद में चलाएं बाद में चलाएं सूचियाँ पसंद पसंदSend us a text In a world of rapid advancements in medical science and biotechnology, bioprocessing is at the forefront of healthcare innovation. Yet, despite remarkable progress, life-saving biotherapeutics remain out of reach for much of the global population. A staggering 80% of patients worldwide lack access to the biotherapeutics they need. While bioprocessing has made impressive strides, the high cost and slow development of these treatments create significant barriers. Addressing these challenges is critical to making innovative therapies widely available. David Brühlmann is launching a special four-part series based on his keynote at the Amphacademy, exploring bioprocessing’s revolutionary journey - from the early days of recombinant insulin to today’s groundbreaking therapies. This series will also highlight strategies to make these innovations more accessible to patients worldwide. From Standardization to Personalization One major challenge is the shift away from platform technologies. Traditionally, antibodies were produced using standardized CHO cell templates and purification steps, but this approach falls short for new modalities. Personalized therapies further complicate the landscape. Autologous cell therapies, for example, require isolating, cultivating, and reinfusing a patient’s own cells. These small-batch processes are labor-intensive, less automated, and often reliant on outdated, paper-driven workflows. Innovations in Bioreactor Design With the rise of sensitive cell therapies, bioreactor design must evolve. Unlike CHO cells, these delicate cells require gentler handling environments. Innovations like acoustic wave bioreactors, bionic bioreactors, and specialized cell screws are emerging to optimize cell growth and improve efficiency. The Complexity and Cost of Cell-Based Products New bioprocessing modalities bring greater complexity. Cell-based therapies and cultivated meats are far more intricate than traditional antibody proteins, making scaling production and ensuring quality especially challenging. High production costs further limit access. Even in regions where these therapies are approved, pricing remains a major barrier. Lowering manufacturing costs is essential to democratizing these life-saving treatments. The shift from basic recombinant proteins to complex cell-based therapeutics is just the beginning. Overcoming these challenges - scaling production, reducing costs, and managing complexity - is key to making breakthrough therapies accessible to all. Next step: Wondering how to develop biomanufacturing processes with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech…
S
Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up, Cell Culture Innovation
1 134: Seamless Seed Trains: Simplify Without Sacrificing Quality with François Carruzzo - Part 2 16:53
16:53 बाद में चलाएं बाद में चलाएं सूचियाँ पसंद पसंद16:53
बाद में चलाएं बाद में चलाएं सूचियाँ पसंद पसंदSend us a text The biotechnology industry is on a transformative path. With emerging technologies and innovative ideas, bioprocessing professionals are poised to revolutionize how therapies are developed and delivered. In this episode of the Smart Biotech Scientist Podcast, host David Brühlmann continues his conversation with François Carruzzo, the CTO of Bioscibex, as they delve into the challenges and opportunities present in the biotech landscape. Bioprocess automation boosts efficiency and scalability in therapeutic production. François Carruzzo explores how automation and sensors simplify processes, cut costs, and enhance reliability - key to making biologics more accessible worldwide. Here are some key lessons Carruzzo learned on his entrepreneurial journey: Seeking and Leveraging Advice as a Startup: For biotechnology entrepreneurs, seeking the right advice is a cornerstone for success. Carruzzo discusses the significance of having a scientific advisor. He highlights the value of external perspectives in helping startups navigate strategic decisions, addressing complex challenges, and innovating effectively. The Role of Networking and Ecosystems: Startup ecosystems and networks play an indispensable role in propelling innovations within the biotech industry. Situated in Lausanne, Switzerland, Bioscibex is well-positioned within a dynamic biopharma ecosystem. Utilizing incubators and networking events, Carruzzo underscores the importance of connecting with other innovative organizations and experts, which can accelerate product development and industry relevance. Customer Engagement as a Key Driver for Innovation: Understanding and integrating the voice of the customer is pivotal in product development. Carruzzo emphasizes starting customer interactions early in the development process. Engaging with potential users before launching a prototype allows companies to tailor products that meet user needs and align with market demands. Carruzzo advises biotech entrepreneurs to validate their ideas through market research and pursue them with commitment. He highlights the challenges of innovation but emphasizes its invaluable rewards. By streamlining processes and prioritizing innovation, the biotech industry can drive progress that benefits both companies and patients worldwide. This episode highlights how breakthrough biotech innovations require strategy, regulatory expertise, and customer focus. Bioscibex’s journey exemplifies technology’s transformative power in the industry. Want to dive deeper into the startup journey and gain insights from entrepreneurs? Episodes 119-120: Innovating Protein Purification Using Synthetic Organelles and AI with Haotian Guo Episodes 107-108: From 1 Billion to 100: How AI is Cracking the Enzyme Discovery Code with David Schönauer Episodes 83-84: The Hidden Potential of Shake Flasks: What Every Biotech Scientist Needs to Know with Jens Bayer Episodes 81-82: Regenerating Muscles: The Future of Autologous Cell-based Therapy with Deana Mohr Connect with François Carruzzo: LinkedIn: https://www.linkedin.com/in/francois-carruzzo Bioscibex: https://bioscibex.com Next step: Wondering how to develop biomanufacturing processes with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment Develop biotherapeutics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhu…
S
Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up, Cell Culture Innovation
1 133: Seamless Seed Trains: Simplify Without Sacrificing Quality with François Carruzzo - Part 1 22:30
22:30 बाद में चलाएं बाद में चलाएं सूचियाँ पसंद पसंद22:30
बाद में चलाएं बाद में चलाएं सूचियाँ पसंद पसंदSend us a text Biologics manufacturing relies heavily on optimizing various stages, yet the seed train step - often overlooked - plays a critical role in determining overall efficiency. The seed train involves expanding cells from a small working cell bank to scales suitable for production bioreactors. Francois Carruzzo, Co-founder and CTO of Bioscibex, is rethinking how this process can be simplified, streamlined, and made more reliable, using a fully automated, closed system. However, the complexity of scaling introduces several risks, including handling errors, contamination, and delays that could derail production timelines. Today, seed train processes involve multiple vessels, open handling, and labor-intensive steps, all of which complicate operations. François identified two prominent challenges: Contamination Risks: Multiple open steps, such as using spin tubes, shake flasks, and wave systems, result in a heightened potential for contamination. Operational Complexity: With multiple campaigns and products running simultaneously, accommodating different media types and containers can become overwhelming. Bioscibex is on the verge of revolutionizing seed train operations with its innovative single-use bioreactor system. François shared how this system addresses traditional shortcomings: Wide Turndown Ratio: Capable of scaling from 30 mL all the way to 30 L within the same vessel, Bioscibex's rocking motion reactor eliminates multiple intermediary steps. Closed Workflow: By maintaining a fully enclosed environment, the system dramatically lowers contamination risks, making bioprocessing more reliable. Continuous Cell Expansion: Unlike traditional methods that involve batch dilutions, Bioscibex supports continuous cell expansion, ensuring optimal growth conditions with reduced downtime. Innovation in seed train processes extends far beyond mere operational efficiency. It lays the groundwork for scalable, consistent biologics production, ensuring therapies can reliably reach clinics faster. By simplifying the mundane yet critical seed train step, his innovation offers a glimpse into the future of stress-free, scalable cell expansion - a vision we’re excited to see unfold. Interested in finding out more about the progress made in cell culture? Take a listen to what our previous guests had to say about it: Episodes 117-118 - Critical Bottlenecks and Breakthroughs in Cell Line Development with Andrea Gough Episodes 113-114: Weighing of Single-Use Bag Systems: Why Traditional Load Cells Are Holding You Back with Anders Tvegaard Episodes 109-110: Spinning Like Earth: Designing Low-Shear Bioreactors for Better Cell Culture with Olivier Detournay Connect with François Carruzzo: LinkedIn: https://www.linkedin.com/in/francois-carruzzo Bioscibex: https://bioscibex.com Next step: Wondering how to develop biomanufacturing processes with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment Develop biotherapeutics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t…
प्लेयर एफएम में आपका स्वागत है!
प्लेयर एफएम वेब को स्कैन कर रहा है उच्च गुणवत्ता वाले पॉडकास्ट आप के आनंद लेंने के लिए अभी। यह सबसे अच्छा पॉडकास्ट एप्प है और यह Android, iPhone और वेब पर काम करता है। उपकरणों में सदस्यता को सिंक करने के लिए साइनअप करें।
Daily Deals
Daily Deals
समान Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up, Cell Culture Innovation
This Week in Evolution is a podcast on the biology of what makes us tick. Hosts Nels Elde and Vincent Racaniello take you through the new evolution that has been revolutionized by the field of genomics and molecular biology.
…
continue reading
A myriad of AI, science, and technology experts explore the real challenges and enormous opportunities facing entrepreneurs who are building the future of health. Raising Health, a podcast by a16z Bio + Health and hosted by Kris Tatiossian and Olivia Webb, dives deep into the heart of biotechnology and healthcare innovation. Join veteran company builders, operators, and investors Vijay Pande, Julie Yoo, Vineeta Agarwala, and Jorge Conde, along with distinguished guests like Mark Cuban, Greg ...
…
continue reading
Flash Forward is a show about possible (and not so possible) future scenarios. What would the warranty on a sex robot look like? How would diplomacy work if we couldn’t lie? Could there ever be a fecal transplant black market? (Complicated, it wouldn’t, and yes, respectively, in case you’re curious.) Hosted and produced by award winning science journalist Rose Eveleth, each episode combines audio drama and journalism to go deep on potential tomorrows, and uncovers what those futures might re ...
…
continue reading
Going Wild with Dr. Rae Wynn Grant is a different kind of nature show about the human drama of saving animals. From a paleoanthropologist who hunts fossils in conflict zones to someone who helped save an endangered species while in prison, in season four we will hear from real-life heroes and nature advocates with widely different expertise and life experiences that led them to be champions for the natural world. Wildlife biologist and host Dr. Rae Wynn-Grant has been studying wild animals i ...
…
continue reading
Come dive into one of the curiously delightful conversations overheard at National Geographic’s headquarters, as we follow explorers, photographers, and scientists to the edges of our big, weird, beautiful world. Hosted by Peter Gwin and Amy Briggs.
…
continue reading
This Week in Microbiology is a podcast about unseen life on Earth hosted by Vincent Racaniello and friends. Following in the path of his successful shows 'This Week in Virology' (TWiV) and 'This Week in Parasitism' (TWiP), Racaniello and guests produce an informal yet informative conversation about microbes which is accessible to everyone, no matter what their science background.
…
continue reading
Best Business Podcast (Gold), British Podcast Awards 2023 How do you build a fully electric motorcycle with no compromises on performance? How can we truly experience what the virtual world feels like? What does it take to design the first commercially available flying car? And how do you build a lightsaber? These are some of the questions this podcast answers as we share the moments where digital transforms physical, and meet the brilliant minds behind some of the most innovative products a ...
…
continue reading
Unexplainable takes listeners right up to the edge of what we know…and then keeps on going. The Unexplainable team — Noam Hassenfeld, Julia Longoria, Byrd Pinkerton, and Meradith Hoddinott — tackles scientific mysteries, unanswered questions, and everything we learn diving into the unknown. New episodes every Wednesday.
…
continue reading
The surprising connections in science and technology that give you the Big Picture. Astronomer Seth Shostak and science journalist Molly Bentley are joined each week by leading researchers, techies, and journalists to provide a smart and humorous take on science. Our regular "Skeptic Check" episodes cast a critical eye on pseudoscience.
…
continue reading
The Naked Scientists flagship science show brings you a lighthearted look at the latest scientific breakthroughs, interviews with the world's top scientists, answers to your science questions and science experiments to try at home.
…
continue reading
Player FM - पॉडकास्ट ऐप
Player FM ऐप के साथ ऑफ़लाइन जाएं!
Player FM ऐप के साथ ऑफ़लाइन जाएं!
))
